GTN Ltd, a London, UK-based provider of a a drug discovery platform, raised £2.1m ($3m) in seed funding.
The round was led by Octopus Ventures and Pentech with participation from existing investor Entrepreneur First.
The company intends to use the funds to recruit for a number of roles within the Machine Learning, Computational Chemistry and Drug Discovery fields.
Led by Professor Noor Shaker, Co-Founder and CEO, GTN has been developing patented technology, Generative Tensorial Networks, which facilitates the search for novel small molecule drugs from within unexplored domains.
The company is currently running collaborations with global Pharmaceutical companies and also has partnerships with research bodies including the Francis Crick Institute.